Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes
- 1 September 2020
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 30 (17) , 127390
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritisBioorganic & Medicinal Chemistry Letters, 2017
- Discovery of novel BTK inhibitors with carboxylic acidsBioorganic & Medicinal Chemistry Letters, 2016
- Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked AtropisomersJournal of Medicinal Chemistry, 2016
- Investigational Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritisExpert Opinion on Investigational Drugs, 2016
- Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid ArthritisACS Medicinal Chemistry Letters, 2015
- The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cellsArthritis Research & Therapy, 2011
- Tyrosine kinases and their substrates in B lymphocytesImmunological Reviews, 2009
- Molecular defects in T- and B-cell primary immunodeficiency diseasesNature Reviews Immunology, 2005
- Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemiaCell, 1993
- The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinasesNature, 1993